XNAS · Healthcare · Diagnostics & Research
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Q1 2026 | 3.87 | 4.28 | +10.59% | $706.6M | ✅ Beat | -17.40% | -18.66% | -14.88% |
| 2026-02-09 | Q4 2025 | 4.21 | 4.67 | +10.93% | $708.5M | ✅ Beat | -4.84% | -19.26% | -9.92% |
| 2025-10-22 |
| Q3 2025 |
| 3.54 |
| 3.86 |
| +9.04% |
| $659.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-04-21 | Q1 2025 | 3.08 | 3.67 | +19.16% | $558.6M | ✅ Beat | -2.32% | +3.18% | +2.35% |
| 2025-02-10 | Q4 2024 | 3.12 | 3.67 | +17.63% | $536.6M | ✅ Beat | -7.52% | -3.88% | -8.35% |
| 2024-10-21 | Q3 2024 | 2.78 | 3.01 | +8.27% | $533.3M | ✅ Beat | -7.47% | -6.68% | -7.60% |
| 2024-07-22 | Q2 2024 | 2.54 | 2.75 | +8.27% | $528.1M | ✅ Beat | -18.27% | -11.89% | -9.49% |
| 2024-04-22 | Q1 2024 | 2.46 | 3.20 | +30.08% | $511.0M | ✅ Beat | +8.21% | +6.37% | +3.60% |
Showing last 8 quarters.